Skip to contentC
Cardiff Oncology, Inc.
C
CRDFCardiff Oncology, Inc. Q1 2020 · 10-Q
Revenue$68.00K$68.00K+9.6% vs Q1 2019 Net Income-$4.09M-$4.09MN/M vs Q1 2019 EPS Diluted-$0.41-$0.41N/M vs Q1 2019 Operating Income-$4,124,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cardiff Oncology, Inc. · CIK 1213037 · Engraved from SEC EDGAR
Free Cash Flowderived-$3,374,000N/M Margins · derivedOperating margin-6064.7%+323.1 pt vs Q1 2019
Net margin-6013.2%+282.6 pt vs Q1 2019
ended Mar 31, 2020 · filed May 7, 2020 · 37 d after period end